Abstract
The bacterium Pseudomonas aeruginosa is known to be associated with nosocomial infections around the world. Pazufloxacin, a potent DNA gyrase inhibitor, is known to be an effective drug candidate. However, it has not been clarified whether the pharmacokinetic (PK)/pharmacodynamic (PD) of pazufloxacin was effective against P. aeruginosa. Herein, we demonstrated that the PK/PD index of pazufloxacin against P. aeruginosa infection is used to optimize the dosing regiments. We constructed an in vivo infection model by infecting P. aeruginosa into the thigh of a mouse to determine the PD, and we measured the serum concentration of pazufloxacin to construct the PK model using high-performance liquid chromatography. The therapeutic efficacy of pazufloxacin was correlated with the ratio of the area under the free concentration time curve at 24 h to the minimum inhibitory concentration (fAUC(24)/MIC), and the maximum free concentration to the MIC (fC(max)/MIC). Each contribution rate (R(2)) was 0.72 and 0.65, respectively, whereas the time at which the free drug concentration remained above the MIC (R(2) = 0.28). The target value of pazufloxacin fAUC(24)/MIC for stasis was 46.1, for 1 log(10) it was 63.8, and for 2 log(10) it was 100.8. Moreover, fC(max)/MIC for stasis was 5.5, for 1 log(10) it was 7.1, and for 2 log(10) it was 10.8. We demonstrated that the in vivo concentration-dependent activity of pazufloxacin was effective against the P. aeruginosa infection, and successfully made the PK/PD model sufficiently bactericidal. The PK/PD model will be beneficial in preventing the spread of nosocomial infections.